Sarah Rhead

Guy's and St Thomas' NHS Foundation Trust - Department of Infection

London

United Kingdom

University of Oxford - Centre for Vaccinology and Tropical Medicine

Oxford

United Kingdom

SCHOLARLY PAPERS

3

DOWNLOADS

1,124

SSRN CITATIONS

1

CROSSREF CITATIONS

0

Scholarly Papers (3)

1.

Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection

Number of pages: 39 Posted: 19 Apr 2021
University of Oxford - Peter Medawar Building for Pathogen Research, GSK plc, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, Imperial College London - Department of Infectious Disease, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, NIHR Imperial Clinical Research Facility, University of Oxford - The Jenner Institute, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - The Jenner Institute, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Wellcome Centre for Human Genetics, University of Oxford - Oxford Vaccine Group, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University College London - Department of Infection, University of Oxford - The Jenner Institute, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Oxford Vaccine Group, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Peter Medawar Building for Pathogen Research, Imperial College London - Department of Infectious Disease, University of Oxford - Oxford Vaccine Group, Imperial College London - Department of Infectious Disease, University of Oxford - Oxford Vaccine Group, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Oxford Vaccine Group, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, NIHR Guy's and St Thomas' Biomedical Research Centre, Imperial College London - Department of Infectious Disease, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Oxford Vaccine Group, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Peter Medawar Building for Pathogen Research, Oxford University Hospitals NHS Foundation Trust, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Department of Paediatrics, University of Oxford - Peter Medawar Building for Pathogen Research, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, Imperial College London - Department of Infectious Disease, University of Oxford - The Jenner Institute, University of Oxford - Chinese Academy of Medical Science Oxford Institute (COI), University of Oxford - Oxford Vaccine Group, Imperial College London - Section of Virology, Guy's and St Thomas' NHS Foundation Trust - Harrison Wing, University of Oxford - The Jenner Institute and Independent
Downloads 656 (74,706)
Citation 2

Abstract:

Loading...

2.

Safety and Immunogenicity of the ChadOx1 nCoV-19 (AZD1222) Vaccine in Children Aged 12-17 Years: A Preliminary Report of a Phase 2, Single-Blind, Randomised Controlled Trial (COV006)

Number of pages: 43 Posted: 20 Dec 2021
University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of London - Institute of Infection and Immunity, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, Independent, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, Independent, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Oxford Vaccine Group and Independent
Downloads 409 (132,967)

Abstract:

Loading...

ChAdOx1 nCoV-19, AZD1222, Safety, Immunogenicity, Adolescent, COVID-19

3.

Durability of ChAdOx1 nCoV-19 (AZD1222) Vaccine and Hybrid Humoral Immunity Against Variants Including Omicron BA.1 and BA.4 Six Months after Vaccination: A Randomised, Phase 1b/2a Trial

Number of pages: 30 Posted: 28 Jul 2022
University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, National Institute For Communicable Diseases Of South Africa - Division of Public Health Surveillance and Response, University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand - Faculty of Health Sciences, University of the Witwatersrand - Reproductive Health and HIV Research Unit (RHRU), Setshaba Research Centre, University of Cape Town (UCT) - Centre for Lung Infection and Immunity, Stellenbosch University - Family Centre for Research with Ubuntu, Soweto Clinical Trials Centre, University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, Setshaba Research Centre, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, Soweto Clinical Trials Centre, University of Cape Town (UCT) - Centre for Lung Infection and Immunity, University of the Witwatersrand, National Health Laboratory Services (NHLS) - National Institute for Communicable Diseases, University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, National Health Laboratory Services (NHLS) - National Institute for Communicable Diseases, National Health Laboratory Services (NHLS) - National Institute for Communicable Diseases, Setshaba Research Centre, National Institute for Communicable Diseases of the National Health Laboratory Service, National Health Laboratory Services (NHLS) - National Institute for Communicable Diseases, National Health Laboratory Services (NHLS) - National Institute for Communicable Diseases, University of Cape Town (UCT) - Centre for Lung Infection and Immunity, University of the Witwatersrand, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of the Witwatersrand - Reproductive Health and HIV Research Unit (RHRU), University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Chinese Academy of Medical Science Oxford Institute (COI), University of Oxford - Oxford Vaccine Group, University of the Witwatersrand and University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit
Downloads 59 (653,618)

Abstract:

Loading...

COVID-19, AZD1222, immunogenicity, durability of protection